JP2015516989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516989A5 JP2015516989A5 JP2015510379A JP2015510379A JP2015516989A5 JP 2015516989 A5 JP2015516989 A5 JP 2015516989A5 JP 2015510379 A JP2015510379 A JP 2015510379A JP 2015510379 A JP2015510379 A JP 2015510379A JP 2015516989 A5 JP2015516989 A5 JP 2015516989A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- nucleic acid
- acid molecule
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 150000007523 nucleic acids Chemical group 0.000 claims 9
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims 7
- 108020004414 DNA Proteins 0.000 claims 6
- 102000053602 DNA Human genes 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 150000003384 small molecules Chemical group 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 1
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000032895 transmembrane transport Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/460,408 US20130039933A1 (en) | 2008-08-04 | 2012-04-30 | Sting (stimulator of interferon genes), a regulator of innate immune responses |
| US13/460,408 | 2012-04-30 | ||
| PCT/US2013/038840 WO2013166000A1 (en) | 2012-04-30 | 2013-04-30 | Modulating immune responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015516989A JP2015516989A (ja) | 2015-06-18 |
| JP2015516989A5 true JP2015516989A5 (enExample) | 2016-06-23 |
Family
ID=49514802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510379A Pending JP2015516989A (ja) | 2012-04-30 | 2013-04-30 | 免疫反応の変調 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2844756A4 (enExample) |
| JP (1) | JP2015516989A (enExample) |
| KR (1) | KR20150004416A (enExample) |
| CN (1) | CN104540945A (enExample) |
| AU (1) | AU2013256468A1 (enExample) |
| CA (1) | CA2907616A1 (enExample) |
| WO (1) | WO2013166000A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6257607B2 (ja) | 2012-06-08 | 2018-01-10 | アデュロ バイオテック，インコーポレイテッド | 癌免疫療法のための組成物および方法 |
| MX361680B (es) | 2012-12-13 | 2018-12-13 | Aduro Biotech Inc | Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso. |
| EP3398616A3 (en) | 2012-12-19 | 2019-01-30 | Board of Regents, The University of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
| SG10201708821RA (en) | 2013-04-29 | 2017-12-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| JP2016518140A (ja) | 2013-05-03 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｉ型インターフェロンの環状ジヌクレオチド誘導法 |
| ES2754269T3 (es) | 2013-05-18 | 2020-04-16 | Aduro Biotech Inc | Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
| CR20160564A (es) | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CA2979215A1 (en) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| CA3006930A1 (en) | 2015-12-03 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
| CN106540260A (zh) * | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用 |
| EP3429596B1 (en) | 2016-03-18 | 2022-08-31 | Immune Sensor, LLC | Cyclic di-nucleotide compounds and methods of use |
| CN106539757A (zh) * | 2016-03-20 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP-脂质体在抗肿瘤中的应用 |
| ES2781474T3 (es) | 2016-04-07 | 2020-09-02 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas útiles como moduladores de proteínas |
| PE20181884A1 (es) | 2016-04-07 | 2018-12-07 | Glaxosmithkline Ip Dev Ltd | Amidas heterociclicas utiles como moduladores de proteinas |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| WO2018144775A1 (en) | 2017-02-01 | 2018-08-09 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| CN106667914B (zh) * | 2017-03-13 | 2022-02-01 | 杭州星鳌生物科技有限公司 | 靶向脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用 |
| EP3692033A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) useful in treating hiv |
| CN111417630B (zh) | 2017-10-05 | 2023-06-06 | 葛兰素史克知识产权开发有限公司 | 干扰素基因刺激因子(sting)的调节剂 |
| CN111194214A (zh) | 2017-10-05 | 2020-05-22 | 葛兰素史密斯克莱知识产权发展有限公司 | 施用sting激动剂的方法 |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| KR20210025016A (ko) | 2018-06-28 | 2021-03-08 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 접합 삼중고리형 헤테로사이클 화합물과 그 치료 용도 |
| TW202104214A (zh) | 2019-04-05 | 2021-02-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| CN114981265B (zh) | 2019-12-18 | 2025-01-03 | Ctxt私人有限公司 | 化合物 |
| EP4075980B1 (en) | 2019-12-18 | 2025-07-23 | Stinginn LLC | Substituted 1,2, 4-triazoles and methods of use |
| US11897888B1 (en) | 2020-04-30 | 2024-02-13 | Stinginn Llc | Small molecular inhibitors of sting signaling compositions and methods of use |
| WO2025262266A1 (en) | 2024-06-21 | 2025-12-26 | Institut National de la Santé et de la Recherche Médicale | Methods of determining the clinical phenotype of patients suffering from hidradenitis suppurativa |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2324044A4 (en) * | 2008-08-04 | 2012-04-25 | Univ Miami | STING (STIMULATOR OF INTERFERON GENES) AS A REGULATOR OF BORROWING IMMUNE REACTIONS |
-
2013
- 2013-04-30 WO PCT/US2013/038840 patent/WO2013166000A1/en not_active Ceased
- 2013-04-30 CA CA2907616A patent/CA2907616A1/en not_active Abandoned
- 2013-04-30 JP JP2015510379A patent/JP2015516989A/ja active Pending
- 2013-04-30 EP EP13784572.3A patent/EP2844756A4/en not_active Ceased
- 2013-04-30 CN CN201380029115.7A patent/CN104540945A/zh active Pending
- 2013-04-30 KR KR20147033632A patent/KR20150004416A/ko not_active Ceased
- 2013-04-30 AU AU2013256468A patent/AU2013256468A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516989A5 (enExample) | ||
| Resnier et al. | A review of the current status of siRNA nanomedicines in the treatment of cancer | |
| Merkel et al. | siRNA delivery to the lung: what's new? | |
| Prichard et al. | Orthopoxvirus targets for the development of new antiviral agents | |
| MX2016000019A (es) | (arnip) gen especifico relacionado con las enfermedades respiratorias, (arnip) que contiene la estructura arn oligo helicoidal, composicion que contiene la misma para prevencion o tratamiento de las enfermedades respiratorias. | |
| JP2012228254A5 (enExample) | ||
| BR112020022546A8 (pt) | Entrega extra-hepática | |
| Pham et al. | Strategies for the design of orally bioavailable antileishmanial treatments | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| NZ730296A (en) | Modified double-stranded rna agents | |
| MX2015010083A (es) | Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos. | |
| UA117098C2 (uk) | Сполука, що містить модифікований олігонуклеотид | |
| WO2014043289A3 (en) | Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof | |
| MX385869B (es) | Agentes de iarn modificados. | |
| IN2015DN02238A (enExample) | ||
| JP2016074736A5 (enExample) | ||
| JP2016513950A5 (enExample) | ||
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| BR112014033004A2 (pt) | oligonucleotídeo para tratamento de pacientes com distrofia muscular | |
| EA201070421A1 (ru) | Микрорибонуклеиновые кислоты | |
| JP2017502668A5 (enExample) | ||
| HUE061596T2 (hu) | Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben | |
| JP2016517888A5 (enExample) | ||
| WO2014066915A3 (en) | Methods and compositions to produce ss-rnai activity with enhanced potency | |
| JP2016530233A5 (enExample) |